Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Myriad Genetics Sees Revenue Rise, Widened Losses in Q3

SAN FRANCISCO, May 7 - Myriad Genetics today reported increased revenue and widened losses for the third quarter of fiscal 2002.


Total revenue for the third quarter ended March 31 was $13.1 million compared with $11.6 million in the year-ago period.


The net loss for the quarter was $3.5 million, or $.15 per share, compared to $1.7 million, or $.07 a share, for the same period a year ago.

R&D spending for the quarter rose to approximately $8.7 million from $8.4 million for the year-ago period. 


The company said it had $125.7 million in cash and investments as of March 31.


Click here for more information.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.